TABLE 2.
Antifungal activities of conventional and new antifungal drugs against 55 clinical S. prolificans isolates
| Incubation period and antifungal | MIC (μg/ml)
|
|||
|---|---|---|---|---|
| Range | Geometric mean | 50% | 90% | |
| 48 h | ||||
| Miconazole | 1–16 | 5.98 | 8 | 16 |
| Terbinafine | 1–32 | 8.34 | 8 | 16 |
| Itraconazole | 2–>32 | >32 | >32 | >32 |
| UR-9825 | 0.5–4 | 1.69 | 2 | 2 |
| Voriconazole | 0.5–8 | 2.79 | 4 | 4 |
| Amphotericin B | 1–>16 | 15.34 | 16 | >16 |
| Posaconazole | 2–>8 | >8 | >8 | >8 |
| Nystatin | 8–32 | 20.35 | 16 | 32 |
| Liposomal nystatin | 8–32 | 19.23 | 16 | 32 |
| 72 h | ||||
| Miconazole | 4–>64 | 9.85 | 8 | 64 |
| Terbinafine | 2–>32 | 19.16 | 16 | 32 |
| Itraconazole | >32 | >32 | >32 | >32 |
| UR-9825 | 0.5–8 | 1.97 | 2 | 4 |
| Voriconazole | 1–8 | 3.29 | 4 | 4 |
| Amphotericin B | 2–>16 | >16 | >16 | >16 |
| Posaconazole | >8 | >8 | >8 | >8 |
| Nystatin | 16–>32 | 32 | 32 | >32 |
| Liposomal nystatin | 16–32 | 32 | 32 | 32 |